The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I trial of T-cell receptor gene therapy targeting KK-LC-1 for gastric, breast, cervical, lung and other KK-LC-1 positive epithelial cancers.
 
Scott Norberg
No Relationships to Disclose
 
Erika Maria Von Euw
No Relationships to Disclose
 
Gordon Parry
Consulting or Advisory Role - T-Cure Bioscience
 
Steven Highfill
No Relationships to Disclose
 
Zulmarie Franco
No Relationships to Disclose
 
James L. Gulley
Research Funding - Astellas Medivation (Inst); Bavarian Nordic (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); ImmunityBio (Inst); Incyte (Inst); Janssen Oncology (Inst); Merck (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - COMBINATION PDL1 AND TGF-BETA BLOCKADE IN PATIENTS WITH HPV+ MALIGNANCIES Publication number: 20200062849 Abstract: The invention provides a method of inhibiting a malignancy associated with human papilloma virus (HPV) comprising administering to a subje
 
Christian S. Hinrichs
Employment - Ipsen (I)
Consulting or Advisory Role - GlaxoSmithKline; PACT Pharma
Research Funding - Kite, a Gilead company (Inst); Neogene Therapeutics; T-Cure Bioscience (Inst)
Patents, Royalties, Other Intellectual Property - NIH patents and royalties related to immunotherapy.